Targeting YTHDF2 can serve as a strategy to suppress cancer and enhance the efficacy of anti‐tumor treatments.[13, 14] Nevertheless, the reported roles of YTHDF2 in HCC are inconsistent and even contradictory,[10, 12, 15, 16] and the therapeutic value of YTHDF2 in HCC treatment remains underexplored. The gene discussed is YTHDF2; the disease is cancer.